Johan Linderoth

801 total citations
24 papers, 562 citations indexed

About

Johan Linderoth is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Johan Linderoth has authored 24 papers receiving a total of 562 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pathology and Forensic Medicine, 13 papers in Oncology and 6 papers in Neurology. Recurrent topics in Johan Linderoth's work include Lymphoma Diagnosis and Treatment (21 papers), Viral-associated cancers and disorders (6 papers) and CNS Lymphoma Diagnosis and Treatment (6 papers). Johan Linderoth is often cited by papers focused on Lymphoma Diagnosis and Treatment (21 papers), Viral-associated cancers and disorders (6 papers) and CNS Lymphoma Diagnosis and Treatment (6 papers). Johan Linderoth collaborates with scholars based in Sweden, Denmark and Norway. Johan Linderoth's co-authors include Mats Jerkeman, Eva Cavallin‐Ståhl, Gunilla Enblad, Mattias Berglund, Martin Erlanson, Mats Ehinger, Michael Dictor, Emina Torlakovic, Stein Kvaløy and Göran Roos and has published in prestigious journals such as SHILAP Revista de lepidopterología, British Journal of Cancer and Experimental Cell Research.

In The Last Decade

Johan Linderoth

23 papers receiving 549 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Johan Linderoth Sweden 12 408 276 171 125 97 24 562
Naohiro Sekiguchi Japan 12 400 1.0× 254 0.9× 209 1.2× 86 0.7× 102 1.1× 61 570
Vera Vanhentenrijk Belgium 12 374 0.9× 241 0.9× 219 1.3× 144 1.2× 143 1.5× 13 571
Darius Juškevičius Switzerland 13 427 1.0× 277 1.0× 171 1.0× 73 0.6× 97 1.0× 32 560
Tiffany Tang Singapore 13 413 1.0× 342 1.2× 97 0.6× 69 0.6× 186 1.9× 34 586
Parth Desai United States 12 295 0.7× 289 1.0× 189 1.1× 91 0.7× 58 0.6× 52 576
Gottfried von Keudell United States 13 293 0.7× 243 0.9× 151 0.9× 179 1.4× 104 1.1× 46 560
Evgenii A. Osmanov Russia 6 352 0.9× 316 1.1× 207 1.2× 110 0.9× 50 0.5× 22 493
Manuel F. Rosado United States 10 333 0.8× 249 0.9× 97 0.6× 58 0.5× 87 0.9× 14 491
Alma María Rodríguez United States 5 344 0.8× 286 1.0× 208 1.2× 215 1.7× 69 0.7× 7 597
Sverker Hasselblom Sweden 14 320 0.8× 209 0.8× 115 0.7× 103 0.8× 145 1.5× 25 494

Countries citing papers authored by Johan Linderoth

Since Specialization
Citations

This map shows the geographic impact of Johan Linderoth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan Linderoth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan Linderoth more than expected).

Fields of papers citing papers by Johan Linderoth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johan Linderoth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan Linderoth. The network helps show where Johan Linderoth may publish in the future.

Co-authorship network of co-authors of Johan Linderoth

This figure shows the co-authorship network connecting the top 25 collaborators of Johan Linderoth. A scholar is included among the top collaborators of Johan Linderoth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johan Linderoth. Johan Linderoth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Holte, Harald, Ingrid Glimelius, Magnus Björkholm, et al.. (2019). No excess long‐term mortality in stage I‐IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. British Journal of Haematology. 188(5). 685–691. 18 indexed citations
4.
Molin, Daniel, Johan Linderoth, & Björn E. Wahlin. (2017). Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry. British Journal of Haematology. 177(3). 449–456. 11 indexed citations
5.
Hasni, Muhammad Sharif, Mattias Berglund, Konstantin Yakimchuk, et al.. (2016). Estrogen receptor β1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker. Leukemia & lymphoma. 58(2). 418–427. 11 indexed citations
6.
Jakobsen, Lasse, Martin Hutchings, Peter de Nully Brown, et al.. (2016). No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish‐Swedish population‐based observational study. British Journal of Haematology. 173(2). 236–244. 17 indexed citations
7.
Glimelius, Ingrid, Sara Ekberg, Johan Linderoth, et al.. (2015). Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time—a population-based comparative study. Journal of Cancer Survivorship. 9(4). 599–609. 29 indexed citations
8.
Joost, Patrick, Mats Ehinger, Patrik Edén, et al.. (2012). Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma. Leukemia & lymphoma. 53(9). 1764–1768. 10 indexed citations
9.
Lindén, Ola, et al.. (2011). Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines. Experimental Cell Research. 317(8). 1179–1191. 12 indexed citations
10.
Enblad, Gunilla, Beatrice Melin, Harald Holte, et al.. (2011). EVALUATION OF THE NORDIC STUDY FOR EARLY STAGE HODGKIN LYMPHOMA in ANNALS OF ONCOLOGY, vol 22, issue , pp 179-180. 22. 179–180. 1 indexed citations
11.
Linderoth, Johan, Heidi Nyman, Mats Ehinger, et al.. (2010). CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leukemia & lymphoma. 51(9). 1643–1648. 10 indexed citations
12.
Dictor, Michael, Mats Jerkeman, Mattias Berglund, et al.. (2009). Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells. American Journal of Hematology. 84(12). 803–808. 26 indexed citations
13.
Ehinger, Mats, Johan Linderoth, Birger Christensson, Birgitta Sander, & Eva Cavallin‐Ståhl. (2008). A Subset of CD5– Diffuse Large B-Cell Lymphomas Expresses Nuclear Cyclin D1 With Aberrations at theCCND1Locus. American Journal of Clinical Pathology. 129(4). 630–638. 33 indexed citations
14.
Andersson, Anne, Gunilla Enblad, Björn Tavelin, et al.. (2008). Family history of cancer as a risk factor for second malignancies after Hodgkin's lymphoma. British Journal of Cancer. 98(5). 1001–1005. 9 indexed citations
15.
Linderoth, Johan, Patrik Edén, Mats Ehinger, et al.. (2008). Genes associated with the tumour microenvironment are differentially expressed in curedversusprimary chemotherapy‐refractory diffuse large B‐cell lymphoma. British Journal of Haematology. 141(4). 423–432. 32 indexed citations
16.
17.
Linderoth, Johan, Mats Ehinger, Måns Åkerman, et al.. (2007). Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B‐cell lymphoma. European Journal Of Haematology. 79(2). 146–149. 23 indexed citations
18.
Linderoth, Johan, Mats Ehinger, Mats Jerkeman, et al.. (2007). CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma. Leukemia & lymphoma. 48(9). 1774–1779. 11 indexed citations
19.
Berglund, Mattias, Ulf Thunberg, Rose‐Marie Amini, et al.. (2005). Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Modern Pathology. 18(8). 1113–1120. 157 indexed citations
20.
Linderoth, Johan, Eva Rambech, & Michael Dictor. (1999). Dominant human herpesvirus type 8 RNA transcripts in classical and AIDS-related Kaposi's sarcoma. The Journal of Pathology. 187(5). 582–587. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naohiro Sekiguchi Breakdown of academic impact, for papers by Vera Vanhentenrijk Breakdown of academic impact, for papers by Darius Juškevičius Breakdown of academic impact, for papers by Tiffany Tang Breakdown of academic impact, for papers by Parth Desai Breakdown of academic impact, for papers by Gottfried von Keudell Breakdown of academic impact, for papers by Evgenii A. Osmanov Breakdown of academic impact, for papers by Manuel F. Rosado Breakdown of academic impact, for papers by Alma María Rodríguez Breakdown of academic impact, for papers by Sverker Hasselblom
Rankless by CCL
2026